From: Plasma metabolomics profiles in Black and White participants of the Adventist Health Study-2 cohort
Subclass | Fold difference (95% CI) | n total metabolites | n significant metabolites | n > 1 | n < 1 | FDR |
---|---|---|---|---|---|---|
Creatine metabolism | 1.20 (1.11, 1.29) | 3 | 3 | 3 | 0 | < 9.0E−05 |
Long-chain monounsaturated fatty acid | 0.61 (0.49, 0.75) | 7 | 7 | 0 | 7 | 9.5E−05 |
Pyrimidine metabolism, thymine containing | 0.73 (0.63, 0.83) | 2 | 1 | 0 | 1 | 1.2E−04 |
Ceramides | 0.74 (0.65, 0.85) | 9 | 8 | 0 | 8 | 1.4E−04 |
Lysophospholipid | 0.75 (0.67, 0.84) | 29 | 24 | 0 | 24 | 1.6E−04 |
Monoacylglycerol | 0.65 (0.54, 0.79) | 16 | 13 | 0 | 13 | 1.6E−04 |
Phosphatidylethanolamine (PE) | 0.70 (0.60, 0.83) | 12 | 10 | 0 | 10 | 1.8E−04 |
Phosphatidylinositol (PI) | 0.75 (0.67, 0.83) | 6 | 6 | 0 | 6 | 2.4E−04 |
Glycerolipid metabolism | 0.77 (0.68, 0.87) | 2 | 2 | 0 | 2 | 2.6E−04 |
Tryptophan metabolism | 0.84 (0.77, 0.92) | 20 | 11 | 0 | 11 | 3.3E−04 |
Diacylglycerol | 0.57 (0.47, 0.68) | 11 | 10 | 0 | 10 | 4.7E−04 |
Pyrimidine metabolism, orotate containing | 0.79 (0.70, 0.90) | 3 | 2 | 0 | 2 | 7.1E−04 |
Long-chain polyunsaturated fatty acid (n3 and n6) | 0.72 (0.61, 0.86) | 17 | 14 | 0 | 14 | 7.7E−04 |
Leucine, isoleucine, and valine metabolism | 0.87 (0.80, 0.94) | 28 | 15 | 0 | 15 | 7.8E−04 |
Lysine metabolism | 0.83 (0.75, 0.92) | 16 | 6 | 0 | 6 | 9.5E−04 |
Fatty acid metabolism (acyl choline) | 0.72 (0.60, 0.87) | 9 | 8 | 0 | 8 | 9.8E−04 |
Xanthine metabolism | 0.49 (0.32, 0.74) | 13 | 12 | 0 | 12 | 1.5E−03 |
Ascorbate and aldarate metabolism | 0.84 (0.75, 0.93) | 6 | 5 | 0 | 5 | 2.2E−03 |
Phosphatidylcholine (PC) | 0.85 (0.77, 0.94) | 19 | 10 | 0 | 10 | 2.4E−03 |
Fatty acid, dihydroxy | 0.85 (0.76, 0.94) | 5 | 3 | 0 | 3 | 2.9E−03 |
Fructose, mannose, and galactose metabolism | 0.79 (0.68, 0.92) | 4 | 1 | 0 | 1 | 3.3E−03 |
Guanidino and acetamido metabolism | 0.73 (0.60, 0.89) | 2 | 1 | 0 | 1 | 3.4E−03 |
Pentose metabolism | 0.85 (0.76, 0.95) | 6 | 4 | 0 | 4 | 4.7E−03 |
Long-chain saturated fatty acid | 0.82 (0.72, 0.95) | 7 | 5 | 0 | 5 | 7.0E−03 |
Dihydroceramides | 0.79 (0.66, 0.94) | 2 | 2 | 0 | 2 | 7.4E−03 |
Pyrimidine metabolism, cytidine containing | 0.84 (0.74, 0.96) | 5 | 2 | 0 | 2 | 1.3E−02 |
Eicosanoid | 0.75 (0.59, 0.95) | 3 | 2 | 0 | 2 | 1.7E−02 |
Chemical | 0.87 (0.78, 0.98) | 20 | 9 | 1 | 8 | 1.9E−02 |
Fatty Acid, monohydroxy | 0.90 (0.82, 0.98) | 19 | 5 | 0 | 5 | 2.0E−02 |
Androgenic steroids | 0.80 (0.66, 0.97) | 21 | 8 | 0 | 8 | 2.1E−02 |
Pantothenate and CoA metabolism | 0.78 (0.63, 0.98) | 2 | 1 | 0 | 1 | 3.0E−02 |
Gamma-glutamyl amino acid | 0.93 (0.86, 1.00) | 15 | 9 | 1 | 8 | 3.4E−02 |
Nicotinate and nicotinamide metabolism | 0.86 (0.75, 0.99) | 5 | 2 | 0 | 2 | 3.6E−02 |
Sphingosines | 0.88 (0.78, 1.00) | 2 | 1 | 0 | 1 | 3.6E−02 |
Purine metabolism, adenine containing | 0.94 (0.88, 1.00) | 5 | 2 | 0 | 2 | 4.0E−02 |
Fatty acid metabolism (acyl carnitine, dicarboxylate) | 0.86 (0.73, 1.01) | 4 | 2 | 0 | 2 | 4.6E−02 |
Sphingolipid synthesis | 0.89 (0.79, 1.00) | 3 | 2 | 0 | 2 | 4.6E−02 |
Phospholipid metabolism | 0.92 (0.84, 1.00) | 6 | 2 | 0 | 2 | 4.7E−02 |